Clinical Trials Industry News More
-
Human Genome Sciences And Glaxosmithkline Announce Positive Results In Second Of Two Phase 3 Trials Of Benlysta™ In Systemic Lupus Erythematosus
11/5/2009
Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) recently announced that BENLYSTA (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE).
-
World’s largest Malaria Vaccine Trial Now Underway In Seven African Countries
11/5/2009
A pivotal efficacy trial of RTS,S, the world’s most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania.
-
Millipore Scientist To Lead PDA Web Seminar On Innovative Testing Methods For Detecting Mycoplasma Contamination
10/28/2009
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, will lead a web-based seminar on detection of Mycoplasma and viral contamination, a subject of heightened interest in biopharmaceutical manufacturing.
-
Icagen Reports Top-Line Results Of Phase IIa Study Of Senicapoc In Exercise-Induced Asthma
10/28/2009
Icagen, Inc. today reported that in a proof-of-concept, Phase IIa exercise-induced asthma study, senicapoc failed to demonstrate improvement in the primary study endpoints, including maximum decrease in FEV1, time to recovery of FEV1 after exercise and area under the FEV1 curve for sixty minutes.
-
TransMolecular’s 131I-Tm601 Shown To Improve Survival In Recurrent Malignant Glioma
10/26/2009
TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, recently announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.
-
Surface Dissolution Imaging Gives Insight Into Bioavailability
10/21/2009
Paraytec has announced that it will be demonstrating an exciting new tool for surface dissolution imaging - the ActiPix SDI300 at the 2009 American Association for Pharmaceutical Scientists (AAPS) meeting in Los Angeles, CA.
-
Transparent Inc. To Introduce Cell-Able, A Unique Human Hepatocyte Array, To U.S. Market At ISSX Meeting
10/20/2009
Transparent, Inc., a bio-venture business headquartered here, announced recently that it will be introducing Cell-able, a human hepatocyte array kit that has the potential to reduce drug development costs and time-to-market for pharmaceutical companies, at its exhibit at the annual meeting of the International Society for the Study of Xenobiotics in Baltimore, Maryland, October 18-22.
-
ACTEMRA Inhibits Progression Of Joint Destruction In RA Patients By Over 80% Compared To Methotrexate Alone
10/20/2009
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, patients with rheumatoid arthritis treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) plus methotrexate (MTX) suffered 81% less damage to their joints compared to those treated with MTX, the current standard therapy, alone1. For patients, this means that their joint damage is significantly reduced, and that they can therefore continue to enjoy their lives without the evolving disability usually associated with the disease.
-
Water Industry Professionals Set To Attend First-Ever Water Experts Virtual Conference Presented By Hach Company On November 5
10/16/2009
Hach Company will present the first Water Experts Virtual Conference on November 5, 2009, from 9am to 6pm Eastern time. This free, Internet-exclusive event gives registrants the opportunity to attend informational conference sessions, get application and product information in virtual trade show booths, download valuable content, and participate in live chat and Q&A sessions with key water experts.
-
World Courier Triples Clinical Trial Storage Capacity Worldwide With Two New Facilities And Client-Driven Expansion
10/15/2009
World Courier is pleased to announce the opening of its newest purpose-driven investigational drug storage facilities in Melbourne (Australia) and Johannesburg (South Africa), bringing its network of GMP (Good Manufacturing Practice)-compliant clinical trial depots to a total of 11 worldwide and providing cost-effective logistical access to two continents critical to the global pharmaceutical industry.
This website uses cookies to ensure you get the best experience on our website. Learn more